FDA Indications for Iloperidone
Iloperidone is FDA-approved solely for the treatment of schizophrenia in adults. 1
Approved Indication
The FDA label explicitly states that iloperidone tablets are indicated for:
- Treatment of schizophrenia in adults 1
This is the only FDA-approved indication for iloperidone. The drug received FDA approval in May 2009 for this specific use 2.
Important Limitations and Warnings
Iloperidone is NOT approved for:
- Dementia-related psychosis in elderly patients (carries a black box warning for increased mortality risk in this population) 1
- Bipolar disorder (despite recent positive clinical trial data showing efficacy for bipolar mania 3, 4, this is not yet an FDA-approved indication)
Clinical Context
While iloperidone is a second-generation atypical antipsychotic that acts primarily through D2/5HT2a receptor antagonism 5, its clinical use is restricted to adult schizophrenia patients. The drug requires titration over 4-7 days to minimize orthostatic hypotension, starting at 1 mg twice daily and reaching target doses of 6-12 mg twice daily 1.
Key prescribing considerations:
- Available only in oral formulation (no injectable form exists) 5, 6
- Requires dose adjustment in CYP2D6 poor metabolizers (reduce dose by half) 1
- Requires dose reduction when co-administered with strong CYP2D6 or CYP3A4 inhibitors 1
- Can prolong QTc interval, requiring careful patient selection 7
The drug's favorable profile regarding extrapyramidal symptoms and akathisia makes it particularly suitable for schizophrenia patients who are sensitive to these side effects 7, but its use remains limited to this single FDA-approved indication.